Resistant Pseudomonas aeruginosa Infections - Pipeline Review, H2 2017

  • ID: 4396108
  • Report
  • 54 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Achaogen Inc
  • AmpliPhi Biosciences Corp
  • Biolytics Pharma
  • ContraFect Corp
  • Inhibrx LP
  • LegoChem Biosciences Inc
  • MORE
Resistant Pseudomonas aeruginosa Infections - Pipeline Review, H2 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Resistant Pseudomonas aeruginosa Infections - Pipeline Review, H2 2017, provides an overview of the Resistant Pseudomonas aeruginosa Infections (Infectious Disease) pipeline landscape.

Pseudomonas aeruginosa has become an important cause of infection, especially in patients with compromised host defense mechanisms. It has an ability to rapidly develop resistance to multiple classes of antibiotics. It is the most common pathogen isolated from patients who have been hospitalized for more than one week. Signs and symptoms include pneumonia, fever, fatigue, itchy rash, bleeding ulcers and headache. Risk factors include age and weakened immune system.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Resistant Pseudomonas aeruginosa Infections - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Resistant Pseudomonas aeruginosa Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Resistant Pseudomonas aeruginosa Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Resistant Pseudomonas aeruginosa Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 7 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively.

Resistant Pseudomonas aeruginosa Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Resistant Pseudomonas aeruginosa Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Resistant Pseudomonas aeruginosa Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Resistant Pseudomonas aeruginosa Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Resistant Pseudomonas aeruginosa Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Resistant Pseudomonas aeruginosa Infections (Infectious Disease)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Resistant Pseudomonas aeruginosa Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Resistant Pseudomonas aeruginosa Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Achaogen Inc
  • AmpliPhi Biosciences Corp
  • Biolytics Pharma
  • ContraFect Corp
  • Inhibrx LP
  • LegoChem Biosciences Inc
  • MORE
Introduction

Resistant Pseudomonas aeruginosa Infections - Overview

Resistant Pseudomonas aeruginosa Infections - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Resistant Pseudomonas aeruginosa Infections - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Resistant Pseudomonas aeruginosa Infections - Companies Involved in Therapeutics Development

Achaogen Inc

AmpliPhi Biosciences Corp

Biolytics Pharma

ContraFect Corp

Inhibrx LP

LegoChem Biosciences Inc

Melinta Therapeutics Inc

Novartis AG

Shionogi & Co Ltd

Resistant Pseudomonas aeruginosa Infections - Drug Profiles

ABPA-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biologic for Multi-Drug Resistant Pseudomonas aeruginosa Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biologic for Pseudomonas Aeruginosa Infection - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biologic for Resistant Pseudomonas aeruginosa Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cefiderocol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CSA-13 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

G-10 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMT-504 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LCB-100200 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies for Gram-Negative Bacterial Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies for Resistant Pseudomonas aeruginosa Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit PcrV for Resistant Pseudomonas aeruginosa Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PEG-2S - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Enzyme to Disrupt Bacterial Cell Wall for Resistant Pseudomonas aeruginosa Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RXP-873 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit LpxC for Resistant Pseudomonas aeruginosa Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit LpxC for Gram-Negative Bacterial Infections and Respiratory Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Resistant Pseudomonas aeruginosa Infections - Dormant Projects

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Resistant Pseudomonas aeruginosa Infections, H2

Number of Products under Development by Companies, H2

Number of Products under Development by Universities/Institutes, H2

Products under Development by Companies, H2

Products under Development by Universities/Institutes, H2

Number of Products by Stage and Target, H2

Number of Products by Stage and Mechanism of Action, H2

Number of Products by Stage and Route of Administration, H2

Number of Products by Stage and Molecule Type, H2

Resistant Pseudomonas aeruginosa Infections - Pipeline by Achaogen Inc, H2

Resistant Pseudomonas aeruginosa Infections - Pipeline by AmpliPhi Biosciences Corp, H2

Resistant Pseudomonas aeruginosa Infections - Pipeline by Biolytics Pharma, H2

Resistant Pseudomonas aeruginosa Infections - Pipeline by ContraFect Corp, H2

Resistant Pseudomonas aeruginosa Infections - Pipeline by Inhibrx LP, H2

Resistant Pseudomonas aeruginosa Infections - Pipeline by LegoChem Biosciences Inc, H2

Resistant Pseudomonas aeruginosa Infections - Pipeline by Melinta Therapeutics Inc, H2

Resistant Pseudomonas aeruginosa Infections - Pipeline by Novartis AG, H2

Resistant Pseudomonas aeruginosa Infections - Pipeline by Shionogi & Co Ltd, H2

Resistant Pseudomonas aeruginosa Infections - Dormant Projects, H2

List of Figures

Number of Products under Development for Resistant Pseudomonas aeruginosa Infections, H2

Number of Products under Development by Companies, H2

Number of Products under Development by Universities/Institutes, H2

Number of Products by Targets, H2

Number of Products by Stage and Targets, H2

Number of Products by Mechanism of Actions, H2

Number of Products by Stage and Top 10 Mechanism of Actions, H2

Number of Products by Routes of Administration, H2

Number of Products by Stage and Routes of Administration, H2

Number of Products by Molecule Types, H2

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Achaogen Inc
  • AmpliPhi Biosciences Corp
  • Biolytics Pharma
  • ContraFect Corp
  • Inhibrx LP
  • LegoChem Biosciences Inc
  • Melinta Therapeutics Inc
  • Novartis AG
  • Shionogi & Co Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll